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Abstract
Introduction: Common symptoms for children with Anderson-Fabry Disease (FD) such as acroparaesthesia and
gastrointestinal manifestations can only be objectively assessed in patients using a valid instrument. To date, no
such instrument exists.
Methods: A preliminary 40-item measure of symptoms and experience with FD, the Fabry-specific Paediatric Health
and Pain Questionnaire (FPHPQ) was developed, but lacked a formal assessment of its measurement properties. The
FPHPQ was used in the Fabry Outcome Survey (FOS), a registry for all patients with a confirmed diagnosis of FD
who are receiving agalsidase alfa, or are treatment naïve and who are managed by physicians participating in FOS.
After an item analysis to explore how items performed and combined into domains, a battery of psychometric
analyses was performed to assess the measurement properties of this new instrument.
Results: Eighty-seven children (ages 4-18 years) completed the questionnaire. Twenty-three items in three
subscales of the questionnaire emerged: pain associated with heat or exertion, pain associated with cold, and
abdominal pain and fatigue symptoms. Internal consistency reliability for all three subscales was good (Cronbach
alpha≥ 0.84). Reliability was equally high for all age groups (4-7, 8-12, and 13-18). Test-retest reliability was high for
all three subscales (intraclass correlation coefficient≥ 0.74). Construct validity was demonstrated by moderate
correlation with brief pain inventory (BPI), KINDL, and EQ-5D. Known group validity showed all subscales were able
to discriminate between Fabry disease severity groups as classified by above or below median of the FOS MSSI
(Mainz Severity Score Index) grade. The heat or exertion subscale was responsive to change in symptoms between
responders and non-responders as defined by change in EQ-5D index scores between the first and second visit.
Conclusions: Preliminary results indicate that the measurement properties of FPHPQ are valid and reliable for
assessing patient-reported symptoms of FD. The questionnaire could be a useful tool for clinicians to understand
the progression of disease and monitor treatment effects. FPHPQ will be further validated and refined as the FOS
registry is continuously adding more patients.
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Introduction
Anderson-Fabry disease (FD) is a rare condition, but the
second most common among the lysosomal storage dis-
eases (LSD) and the only X-linked sphingolipidosis [1,2].
It is an inherited disorder caused by a deficiency of
alpha-galactosidase A (GLA) that results in a slowly pro-
gressive disease with premature death in adult males and
some females due to cardiac, renal or central-nerve-
system (CNS) events [2]. FD is rare with an estimated
incidence of 1 in 40,000 to 60,000 males, with clinical
heterogeneity in female patients [3-6]. The disease typic-
ally begins in childhood and can be diagnosed by measur-
ing the level of alpha-galactosidase activity; however, this
may be misleading in female heterozygotes probably due
to the random nature of X-inactivation [7]. Molecular
analysis of the GLA gene is the most accurate method of
diagnosis, and many mutations which cause the disease
have been noted.
Characteristic features of FD include episodes of
neuropathic pain [8]. Other symptoms may include
fatigue, nausea, dizziness, gastrointestinal symptoms
such as diarrhoea, a decreased ability to sweat, angioker-
atoma, cornea verticillata and hearing impairment may
also occur in childhood.
In rare conditions such as FD, close and prospective
monitoring of as many patients as possible is important
to gain a better understanding of the natural history of
the disease and the rate of disease progression. Add-
itionally, to assess the impact of treatments such as en-
zyme replacement therapy (ERT), a valid disease-specific
measure is required. Because no instrument to assess
the typical manifestations of the disease existed, the
Fabry-specific Paediatric Health and Pain Questionnaire
(FPHPQ) was developed and has been used to address
the most commonly reported symptoms experienced by
children with FD followed in a Fabry registry – the Fabry
Outcome Survey (FOS; sponsored by Shire Human
Genetics Therapies).
The preliminary FPHPQ was a 40-item questionnaire
on children’s symptoms and experience with FD devel-
oped by the FOS Paediatric Working Group - an inter-
national group of dedicated and experienced clinicians.
The FOS Paediatric Working Group set out to develop a
tool that would both identify disease burden in children
that affected their quality of life but also in the future
once validated, could be used to monitor treatment
effects. The questions were specifically chosen based on
what the clinical experts knew at the time of the subject-
ive early clinical manifestations of FD.
FOS is the world's most comprehensive database on
medical outcomes of patients with FD. FOS is designed
as an international multi-centre, open-label registry [9].
It is open to all patients on, or candidates for ERT
with agalsidase alfa. Patients with FD entered into the
database but not receiving ERT are also followed in
order to gain insight into the natural history of the
condition. The principal aim of FOS is to collect and
disseminate information about the long-term course of
the disease, especially in patients treated with agalsidase
alfa. In order to guide treatment, relevant data recorded
on the FOS database are being made available to the
treating physician on an individual patient basis. Ques-
tions to the database aimed at helping FOS physicians
in their routine clinical practice and patient management
to be handled swiftly [9].
The purpose of this study is to present the psychometric
validation of the FPHPQ, as well as to explore the under-
lying concepts measured and their dimensionality.
Methods
Data were obtained from the FOS. The inclusion criteria
were patients of both sexes with a confirmed diagnosis
of FD, who were on, or were candidates for, ERT with
agalsidase alfa. The exclusion criteria were patients
who were treated with an ERT other than agalsidase
alfa or were actively enrolled in blinded trials so not
eligible for enrolling in the FOS. FOS was performed
in accordance with the recommendations of Declaration
of Helsinki. Where necessary, participating centres fol-
lowed their respective national and/or local regulations
regarding Ethics Committee/Institution Review Board
requirements.
An internet-based application was used for entering
data into the FOS database. Data were entered into the
database by the responsible FOS physician or designee.
The patients self-reported the survey instruments includ-
ing the FPHPQ, and responses were entered into the
database through the internet application. The cut-off
date for this analysis was April, 2010.
Patients were followed as long as the physician found it
appropriate. Only data collected during normal routine
examinations were requested. At screening/baseline visit,
age and gender, comorbidities, concomitant medication,
and FOS - Mainz Severity Score Index (FOS MSSI)
[10,11] were collected. FPHPQ and other patient reported
outcome (PRO) instruments were administered at subse-
quent visits. Given that FOS is an international, multi-
centre, open survey, the PRO questionnaires were avail-
able to participating patients in their respective languages
for most of the countries. Because FD is a rare disease, it
was necessary to pool data of multiple languages to be
able to include patients with a wide range of disease
severity and to ensure a sufficient sample size for data ana-
lysis. Taking into consideration the language difference,
efforts have been made to harmonize these questionnaires
so that answers can be interpreted in international ana-
lyses. In addition, the translations were reviewed by bi-
lingual clinical experts with particular scrutiny of wording
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appropriate for children. These patient-completed ques-
tionnaires are briefly described below.
Fabry-specific Paediatric Health and Pain Questionnaire
(FPHPQ)
The FPHPQ assesses disease specific symptoms such as
sweating, pain, dizziness and tiredness, heat and cold
intolerance, swollen eyelids, gastrointestinal symptoms,
feeling thirsty, difficulty hearing, ringing or buzzing noise
in the ears, and ability and enjoyment to participate in
sports. The FPHPQ measures the frequency of each spe-
cific symptom using a 5-point Likert scale (always, often,
sometimes, seldom, and never), plus one item that mea-
sures the pain intensity using a 0-10 numeric rating scale.
In addition, two items require numeric responses about
the number of times experiencing onset of pain and the
number of school days missed. Finally, there are two
items with ‘yes’ or ‘no’ response asking about difficulty in
hearing and other problems not mentioned. There are
three separate age-specific versions for children aged 4-7,
8-12 and 13-18 years with questions that are phrased age
appropriately. The parents of children aged 4-7 complete
the FPHPQ; children aged 8 and above complete the
questionnaire themselves. Translations of the FPHPQ are
available in Spanish, Swedish, English, Norwegian,
French, Dutch, Italian, and German.
FOS - Mainz Severity Score Index (FOS MSSI)
The MSSI is a clinical scoring system developed to assess
the severity of signs and symptoms of FD and to monitor
the progress of individual patients during ERT. The FOS
MSSI is an adaptation of the MSSI scoring system for use
in FOS and has been shown to be a useful and valid tool
to evaluate disease severity and progression in adult
patients with FD [10,11].
The Brief Pain Inventory (BPI)
The BPI questionnaire is a validated tool developed to
capture the “sensory” dimension of pain on a 0–10 numer-
ical rating scale. It includes four pain items to capture
the variability of pain over time and seven items assessing
the “reactive” dimension of pain (interference with daily
function) [12,13]. Initially developed to assess pain
related to cancer, the BPI has shown to be an appropriate
measure for pain caused by a wide range of clinical con-
ditions including FD [14,15].
The KINDL
The KINDL questionnaire is a generic validated ques-
tionnaire developed for use in children and adolescents
to evaluate the impact of health conditions on everyday
living and quality of life (QOL) [16,17]. The KINDL
questionnaire comprises 24 items using a 5-point Likert
scale (never, seldom, sometimes, often, all the time)
and includes six subscales depicting physical well-being,
emotional well-being, self-esteem, family, friends, and
everyday functioning (school or nursery school/
kindergarten).
The EQ-5D
The EuroQol valuation instrument, or EQ-5D, is
an international standardized instrument designed to
measure health and to allow the elicitation of patient
and/or general population preference values for a wide
range of standardized health states [18].
The EQ-5D self-report questionnaire defines health
in terms of five dimensions: mobility, self-care, usual
activities, pain or discomfort, and anxiety or depression.
It also includes the respondents’ perception of their
overall health on the visual analogue scale (EQ VAS),
where 0 and 100 denote the worst and the best health
states, respectively [19]. The EQ-5D has been used in
previous FD studies [20,21].
Statistical analysis: item analysis, reliability, validity,
and responsiveness
A battery of psychometric analyses, described below, was
performed to a) identify poorly performing items and b)
to assess the measurement properties of the instrument
once these items were excluded. All analyses were con-
ducted in several iterative steps with the use of Stata/MP
Ver. 11.0 [22], with the exception of the factor analysis
which was performed using Mplus Ver. 6.0 [23].
First, the distributional characteristics of each of the
items (e.g., % missing, % at floor and ceiling, skewness
and kurtosis) were reviewed to identify poorly per-
forming items. Items were flagged for potential exclusion
if the distribution of responses was highly skewed or
kurtotic or they showed a floor or ceiling effect
(minimum/maximum response > 67% of patients).
Exploratory factor analysis (EFA) was also used as part of
the initial item analysis to help identifying overlapping or
redundant items. Items with factor loadings <0.34 (i.e., less
than 10% of variance explained) on their primary subscale
were flagged for possible deletion. Yes/no items were
excluded as these violate the distributional assumptions of
EFA. The final decision of item inclusion or exclusion was
based on all of the psychometric analyses, and input from
the clinical and instrument development experts.
After the exclusion of items from above, a follow-up
EFA was conducted to investigate the dimensionality of
the items retained. The purpose of the follow-up EFA
was to identify items that cluster into conceptually
related subscales as well as items that lacked or had
weak relationships with the other items and did not be-
long to a specific subscale. Three types of rotation were
consistently used to help interpret simple structure
(quartimax and varimax, which are orthogonal rotations;
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and oblique, which allows correlations between sub-
scales). A scoring algorithm was developed following the
final selection of the items to be included in the
instrument.
Next, the psychometric properties of the FPHPQ sub-
scales that emerged from the follow-up EFA were exam-
ined. The psychometric analyses included descriptive
statistics of the subscales and their internal consistency
reliability, test-retest reliability, validity and responsive-
ness to change. The internal consistency of the FPHPQ
subscales was assessed using Cronbach’s formula for co-
efficient alpha, and whenever Cronbach’s alpha exceeded
0.70 it was considered having good internal consistency
reliability. The analysis for test-retest reliability of the
FPHPQ involved calculating the intraclass correlation
coefficient (ICC) based on data of those who reported
no change on the patient global impression of change
(PGIC) from first to second visit. An ICC of >0.70 among
stable subjects is considered acceptable to demonstrate
test-retest reliability [24].
Validity refers to the extent to which the instrument
measures what it is intended to measure [25]. To demon-
strate construct validity, the score of an instrument should
be correlated with scores of other validated instruments
that measure similar concepts. The construct validity of
the FPHPQ subscales was evaluated through correlation
with the scores of the criterion measures BPI, KINDL,
and EQ-5D. Rank order correlations were calculated and
were expected to be ≥ 0.30 and statistically significant.
Known-group validity is the extent that the average
scores of the FPHPQ are significantly different among
groups of FD patients with different level of disease
severity. Analysis of variance (ANOVA) was used to
examine the FPHPQ scores by the FOS MSSI grades.
Responsiveness (or ability to detect change) refers to
the extent that the score of an instrument reflects the
changes in the patient’s condition. The change of the
score should be in sync with the direction of the con-
dition: improving, worsening or unchanged. Patients
with improving condition should have significantly better
scores than the patients with worsening or unchanged
condition. The magnitude of the score change can also
be used to guide score interpretation. Change measured
as standardized effect sizes with 0.20 denotes a small and
not clinically relevant change; 0.50 denotes a moderate
and clinically relevant change; and 0.80 or above denotes
a large and clearly relevant change [26]. A preliminary
assessment of responsiveness of the FPHPQ was made by
examining the amount of change in FPHPQ subscale
scores between responders versus non-responders with
responder defined as EQ-5D score increased 0.1 point
from first to second visits, and separately with responder
defined as BPI average pain and worst score rating
decreased 20%, also from first to second visits.
Results
The FOS was conducted in 19 countries countries that
included Argentina, Australia, Austria, Belgium, Canada,
Czech Republic, France, Germany, Hungary, Italy, Japan,
the Netherlands, Norway, Slovenia, Spain, Sweden,
Switzerland, United Kingdom, and United States. Out of
the 299 children registered in FOS at the cut-off time of
this study, responses from 87 children (aged 4-18 years)
that completed the questionnaire in eight of the coun-
tries were used for these analyses. Number of patients,
response rate for the FPHPQ, and average study period
in FOS are shown in Table 1.
Demographic and clinical characteristics of the 87 chil-
dren included in this analysis, displayed by the three age
cohorts, are shown in Table 2. More than 50% of the
sample was in the oldest age group (13-18 years), and the
gender distribution was even. Table 3 displays the
descriptive statistics for the other PRO instruments: BPI,
KINDL and EQ-5D at first visit.
Item analysis
Among the original 40 items in the FPHPQ, 27 items
were retained after investigation of descriptive statistics
analysis and the initial EFA. The main reasons for dele-
tion were high proportion (>80%) of missing responses
Table 1 Number of patients at data cut-off date, response rate, and average study period by country
Number of Patients at
Data Cut-off Date (Total N = 299)
Patients Completed
FPHPQ (Total N= 87)
Response
Rate (%)
Average Study
Period (Years)
Country N % N %
Argentina 17 6% 12 14% 71% 2.44
Australia 8 3% 6 7% 75% 4.19
Belgium 6 2% 2 2% 33% 5.11
Canada 17 6% 7 8% 41% 4.06
Germany 53 17% 24 28% 45% 3.79
Spain 17 6% 9 10% 53% 2.34
Italy 25 8% 9 10% 36% 5.46
United Kingdom 40 13% 18 21% 45% 3.40
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or a high proportion (>67%) of floor effects (4 items)
indicating low relevance of the item, and high skewness
or kurtosis (2 items). Based on the initial EFA, items with
high uniqueness (high error) and/or communality esti-
mates (multiple R2) below 0.3 were also deleted (3 items).
Items including binary responses (Yes/No) were also
excluded from the initial EFA (4 items).
These 27 items retained were classified into symptom-
related (23 items) and outcome-related (4 items).
Symptom-related items included items asking about
pain, burning sensation, tiredness, diarrhoea, and bloating
in various conditions. The outcome-related items included
items that assess if children like playing sports, participate
in sports, get tired when playing sports, and get more tired
compared to friends; they were analyzed separately and
were used for descriptive purposes. Only the symptom-
related items were included in the follow-up EFA to iden-
tify specific subscales within the FPHPQ.
EFA on the 23 symptom-related items identified was
conducted using three different rotations: orthogonal
(varimax and quartimax) and oblique (oblimin) rotations.
Factor loadings from oblique rotation are shown in
Table 4. Results suggested that the 23 symptom-related
items clustered into three subscales: pain associated with
heat or exertion; pain associated with cold; and abdom-
inal pain and fatigue symptoms. The eigenvalues for
these subscales were 8.90, 3.10 and 1.53, respectively,
which accounted for 59% of the total variance.
Scoring algorithm
For the validation purposes of the FPHPQ, the five
graded Likert-type response options were transformed
into numeric variables in the following way: 0 =Never,
1 = Seldom, 2 = Sometimes, 3 =Often, 4 =Always. Then,
each of the subscales was scored by computing the raw
sum of responses to each of its items, with equal weight
to all the items. A higher subscale score reflects more
severe symptoms, or worse health.
Reliability, validity, and responsiveness
The Cronbach alphas were 0.94, 0.85, and 0.85 for pain
associated with heat or exertion, pain associated with
cold, and abdominal pain and fatigue subscales, respect-
ively, showing good internal consistency reliability across
all age groups. Scores between first and second visits
were used to assess the test-retest reliability. Time be-
tween first and second visit varied: less than a month for
more than half of the children (52.63%), between one
Table 2 Patient characteristics
All ages (N = 87) Age group 4-7 (N = 10) Age group 8-12 (N = 30) Age group 13-18+ (N= 47)
N % N % N % N %
Gender
Female 43 49% 4 40% 16 53% 23 49%
Male 44 51% 6 60% 14 47% 24 51%
Treated with Agalsidase Alfa
No 37 43% 7 70% 17 57% 13 28%
Yes 50 57% 3 30% 13 43% 34 72%
FOS MSSI
Mild (<20) 81 93% 10 100% 27 90% 44 94%
Moderate (20-40) 3 3% 0 0% 1 3% 2 4%
Missing 3 3% 0 0% 2 7% 1 2%
Table 3 BPI, KINDL, and EQ-5D scores
(N = 87) Mean St. Dev % Missing
BPI Scores
Worst pain last 24 hours 2.53 2.86 63%
Least pain last 24 hours 0.75 1.44 63%
Average Pain 2.03 2.09 63%
Pain right now 0.72 1.71 63%
Average interference score 0.76 1.47 57%
KINDL Scores
Physical health 1.46 0.68 46%
General feeling 1.22 0.48 46%
Personal feeling 2.58 0.99 47%
Family 2.38 0.70 47%
Friends 2.88 0.89 48%
School 2.01 0.91 51%
Stayed in hospital 0.37 0.49 53%
Illness 1.11 0.69 57%
EQ-5D Scores and Utilities
Mobility 1.11 0.31 46%
Self care 1.00 0.00 46%
Usual activities 1.11 0.31 46%
Pain/discomfort 1.53 0.55 46%
Anxiety/discomfort 1.09 0.28 46%
EQ-5D utility 1.00 0.00 46%
EQ-5D VAS 1.11 0.31 46%
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Table 4 EFA – Symptoms items, oblique rotation*
Item Pain Associated
with Heat or
Exertion
Pain Associated
with Cold
Abdominal Pain
& Fatigue
Uniqueness
23d Get burning sensations in fingers and toes when playing? 0.94 −0.09 0.04 0.16
22d Get shooting pains in fingers and toes when playing? 0.90 −0.02 0.01 0.21
22b Get shooting pains in fingers and toes when it is hot? 0.81 0.22 −0.21 0.20
23a Get burning sensations in fingers and toes when fever? 0.80 −0.09 0.15 0.35
22a Get shooting pains in fingers and toes when fever? 0.79 −0.09 0.22 0.32
2a In hot surroundings, pain? 0.77 0.26 −0.22 0.22
20 Upsetting pain? 0.72 −0.06 0.30 0.35
23b Get burning sensations in fingers and toes when it is hot? 0.70 0.34 −0.11 0.24
26 Number of times of sudden onset of pain? 0.49 0.19 0.21 0.54
22c Get shooting pains in fingers and toes when it is cold? 0.06 0.82 0.09 0.23
3a In cold surroundings, pain? 0.12 0.72 −0.12 0.43
23c Get burning sensations in fingers and toes when it is cold? 0.26 0.66 0.02 0.33
25 Muscle pain? −0.09 0.60 0.37 0.44
24 Joint pain? 0.00 0.54 0.33 0.50
7 After eating, bloated or full? 0.03 0.08 0.73 0.42
6 Pain gets worse with eating? 0.20 −0.12 0.71 0.45
9 Diarrhea? 0.05 0.05 0.67 0.51
5 Pain in the tummy? 0.09 0.01 0.63 0.57
10 Tummy pain with diarrhea? −0.11 0.35 0.53 0.54
13 Frequently feel thirsty? −0.18 0.33 0.51 0.60
12 Often wake up during the night to go to toilet? −0.02 0.13 0.48 0.73
2c In hot surroundings, tiredness? 0.24 0.23 0.46 0.53
3c In cold surroundings, tiredness? 0.15 0.32 0.40 0.59
* Other rotations yielded nearly identical results.
Table 5 Construct validity – FPHPQ correlations with EQ-5D, BPI, and KINDL
FPHPQ
Pain Associated
with Heat or Exertion
Pain Associated
with Cold
Abdominal Pain
& Fatigue
EQ-5D Utility −0.43* −0.31* −0.35*
BPI Pain Interference Score 0.25 0.33* 0.35*
BPI Pain Intensity
Worst Pain 0.22 0.39* 0.32
Least Pain 0.21 0.12 0.19
Average Pain 0.01 0.04 0.06
Pain Right Now −0.02 0.07 −0.04
KINDL
Physical Health 0.22 0.39* 0.43*
General Health −0.11 0.07 0.16
Personal Health −0.35* −0.47* −0.29
Family 0.08 −0.20 −0.17
Friends −0.25 −0.43* −0.27
School −0.23 −0.03 −0.05
Illness 0.44* 0.32* 0.27
Correlations > 0.30 are in bold.
* indicates correlation coefficient is significant at 5% level of confidence.
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and two months for more than a third (36.84%) and be-
tween two and three months (10.53%) for the rest. The
ICCs were 0.90, 0.74, and 0.77 for pain associated with
heat or exertion, pain associated with cold, and abdom-
inal pain and fatigue subscales, respectively, showing
good test-retest reliability across all age groups.
Tests for construct validity indicated that each sub-
scale measured unique patient symptom experiences and
was correlated with other instruments in expected ways,
as shown in Table 5. Correlations between the three sub-
scales and the EQ-5D index score were in the moderate
range (0.31 to -0.43) and statistically significant at
p < 0.05. The correlation between the pain associated
with cold, and abdominal pain and fatigue subscales with
the BPI pain interference score was in the moderate
range (0.33 and 0.35, respectively) and statistically sig-
nificant at p < 0.05. However, the correlation between
the pain associated with heat or exertion subscale and
BPI pain interference score was a little lower at 0.25.
Likewise, the correlation between the pain associated
with cold, and abdominal pain and fatigue subscales with
the BPI worst pain item were in the moderate range
(0.39 and 0.32, respectively) and statistically significant
at p < 0.05. Still, the correlation between the pain asso-
ciated with heat or exertion subscale and BPI worst pain
item was 0.22. Finally, the three FPHPQ subscales were
modestly correlated with the KINDL physical health
(0.22 to 0.43), personal feelings (-0.35 to 0.47), friends
(-0.25 to -0.43), and illness (0.27 to 0.44) suggesting that
the symptom components of the FPHPQ are related to
the physical health and social domains measured by the
KINDL.
To assess known-group validity, FOS MSSI grade was
used to classify patients into two groups for comparison
according to disease severity. Using the FOS MSSI be-
tween 20-40 as the criterion, only three patients were
classified as moderate severity versus 81 patients as mild
severity (FOS MSSI < 20), so the sample size of the mod-
erate severity group was too small for the statistical
comparison. Therefore, for this study the median FOS
MSSI of the sample (median = 10.5) was used to classify
the patients into above and below median groups. The
ANOVA results in Table 6 show significant difference
for all three FPHPQ subscale average scores across the
above and below median groups. The known-group val-
idity of the FPHPQ was therefore demonstrated with the
significant difference between the subscale average
scores of the two groups.
Responsiveness of FPHPQ subscale scores was demon-
strated by examining whether the average subscale score
change from first to second visit was significantly
different between the responder and the non-responder
groups. Three definitions of responder were used: 1)
responder as EQ-5D index score increased 0.1 point
from first to second visits; 2) responder as BPI average
pain rating decreased 20% from first to second visits; 3)
responder as BPI worst pain rating decreased 20% from
first to second visits. Based on the EQ-5D definition,
among the 87 patients, 10 were identified as responders
and 31 as non-responders, the rest with missing data.
The intervals between the two visits ranged from 3 to
56 months. Using ANOVA, as shown in Table 7, the
average score changes between the responder and non-
responder groups were significantly different for pain
Table 6 Known-groups validity of the FPHPQ subscales: ANOVA by FOS MSSI severity groups at baseline
FPHPQ Subscales N FPHPQ score Mean (SD) F-test P Value
Pain Associated with Heat or Exertion 0.0261
Severity score below median 35 9.7 (10.49)
Severity score above median 39 15.2 (10.28)
Pain Associated with Cold 0.0175
Severity score below median 32 6.9 (7.05)
Severity score above median 36 10.8 (5.94)
Abdominal Pain & Fatigue 0.0341
Severity score below median 36 1.9 (2.67)
Severity score above median 40 3.5 (3.78)
Table 7 Responsiveness for the FPHPQ subscales using EQ-5D definition
FPHPQ Subscales Responder – EQ-5D Score
Change> 0.1 from Visit 1 to 2
Non-responder – EQ-5D
Score Change< 0.1 from
Visit 1 to 2
F-Test P Value
N Mean (SD) N Mean (SD)
Pain Associated with Heat or Exertion 10 −3.5 (6.40) 31 2.4 (6.80) 0.0197
Pain Associated with Cold 10 −0.1 (1.94) 31 0.3 (2.56) 0.6725
Abdominal Pain & Fatigue 10 0.7 (3.25) 31 −0.5 (3.61) 0.3600
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with heat and exertion subscale, but were not signifi-
cantly different for pain with cold or for abdominal pain
and fatigue subscale. Based on the BPI average pain def-
inition, there were only 5 responders versus 16 non-
responders, and the rest with missing data. The intervals
between the two visits ranged from 3 to 46 months.
Based on the BPI worst pain definition, there were only
two responders versus 19 non-responders, and the rest
with missing data. Responsiveness using the BPI average
pain or worst score to define responders was not assessed
owing to the small sample size.
Discussion
Establishing the psychometric properties of a measure,
especially a new measure, is critical especially when this
is used to monitor patients over time [24,25,27]. In FD, a
rare condition with a low prevalence, no valid and reliable
measure for monitoring patient progress under treatment
existed [7-9,28]. Well established psychometric properties
are a prerequisite for careful monitoring of patient health,
for scientific publication and successful regulatory submis-
sions. By careful item reduction, a more efficient measure
can be created, which has benefits for use in clinical prac-
tice or longitudinal studies to evaluate treatment benefits.
The item analysis of FPHPQ showed that 27 of the
40 items met the psychometric property requirement
to be retained in the instrument. EFA results showed a
potential 3-factor structure for the 23 symptom items:
pain associated with heat or exertion, pain associated
with cold, and abdominal pain and fatigue symptoms. All
three subscales showed excellent internal consistency
reliability and the test-retest reliability. Reasonable pat-
terns of relationships for construct validity of all three
subscales were shown, especially relationships between
EQ-5D and BPI pain interference score. In addition, the
three FPHPQ subscales were correlated with the physical
health and social domains as measured by the KINDL.
Known-group validity was demonstrated by significant
difference in average scores for all three subscales be-
tween groups divided by FOS MSSI median score. A
small number of responders (n = 10) was identified based
on the definition of EQ-5D score increase of 0.1. The
major limitation of the study is the small number of
patients involved that limited the feasibility of some psy-
chometric assessments, specifically confirmatory factor
analysis (CFA) to confirm the factor structure of 3 factors
and responsiveness to determine the FPHPQ’s ability to
detect change in patients clinical condition. Because FD
is a rare disease, it was necessary to pool the data from
various countries to have sufficient sample size. Even so,
the sample size of the pooled data was still not large
enough to take into consideration of the possible lan-
guage differences between the countries; which is another
limitation of this study. In the future, when the sample
size allows, FPHPQ should be evaluated for existence of
language differences. The study was further limited by
the widely variable interval between physician visits and
the high percentage of missing data. These hampered the
statistical comparisons and the generalization of the
study results. FD research would benefit a lot from good
data collection and physicians should be encouraged to
maintain regular patient follow-up visits and adhere to
the FOS registry guidance. The FOS registry is continu-
ously adding patients, so current results should be con-
sidered as preliminary and need to be validated again
once a larger sample of FD patients has been accumu-
lated in the registry [9,29].
Exploration of further applications of the use of the
FPHPQ should be considered. Because of the rarity of
the condition there is a need to improve the understand-
ing of FD and facilitate early detection to avoid delays in
its diagnosis and treatment [9,28]. Performing further
item reduction to achieve a streamlined screening instru-
ment for use in clinical practice to detect discrete but
typical symptoms indicative of FD would be an important
future objective. Additionally, the analysis of potential
differences by subgroups, such as by age cohort or be-
tween countries, should be considered in the future [29].
In conclusion, preliminary results of psychometric ana-
lyses of the FPHPQ are very satisfactory as the three sub-
scales (composed of 23 items) exhibit very satisfactory
measurement properties in terms of reliability and validity.
The large score difference for responsiveness in the pain
associated with heat or exertion subscale indicates that
this subscale reflects an important aspect of FD from the
patient perspective that captures salient patient experi-
ences. The FPHPQ questionnaire is a useful tool for clini-
cians to understand the severity and progression of FD in
childhood and to document treatment benefits over time.
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